Effects of Combination Therapy With Alpha-1 Blocker (Sustained-Release Preparation of Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in the Treatment of Patients With Mild to Moderate Essential Hypertension Accompanied by Metabolic Syndrome.

Trial Profile

Effects of Combination Therapy With Alpha-1 Blocker (Sustained-Release Preparation of Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in the Treatment of Patients With Mild to Moderate Essential Hypertension Accompanied by Metabolic Syndrome.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 May 2013

At a glance

  • Drugs Bunazosin; Doxazosin; Valsartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jun 2008 The expected completion date for this trial is now 1 Sep 2008 as reported by clinicaltrials.gov.
    • 14 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top